This article is more than 5 years old. Information may no longer be current.

ICo Therapeutics files FDA application for antisense inhibitor for neovascular eye diseases

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CARLSBAD, Calif. — ICo Therapeutics, a licensee of Isis Pharmaceuticals, has filed an investigational new drug application with the U.S. Food and Drug Administration for its antisense inhibitor for the treatment of eye diseases including age-related macular degeneration and diabetic retinopathy, according to a press release from Isis.

The antisense drug is a second-generation inhibitor of c-Raf kinase, an enzyme associated with ocular neovascularization, according to the release.

ICo will pay Isis a milestone payment based on the filing, company officials said in the release.